FI3697794T3 - 3-(5-fluoribentsofuran-3-yyli)-4-(5-metyyli-5h-[1,3]dioksolo[4,5-f]indol-7-yyli)pyrroli-2,5-dionin kiinteitä muotoja - Google Patents
3-(5-fluoribentsofuran-3-yyli)-4-(5-metyyli-5h-[1,3]dioksolo[4,5-f]indol-7-yyli)pyrroli-2,5-dionin kiinteitä muotojaInfo
- Publication number
- FI3697794T3 FI3697794T3 FIEP18797367.2T FI18797367T FI3697794T3 FI 3697794 T3 FI3697794 T3 FI 3697794T3 FI 18797367 T FI18797367 T FI 18797367T FI 3697794 T3 FI3697794 T3 FI 3697794T3
- Authority
- FI
- Finland
- Prior art keywords
- solid form
- theta
- form according
- diffraction pattern
- ray powder
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762572603P | 2017-10-16 | 2017-10-16 | |
| PCT/US2018/056083 WO2019079299A1 (en) | 2017-10-16 | 2018-10-16 | SOLID FORMS OF 3- (5-FLUOROBENZOFURAN-3-YL) -4- (5-METHYL-5H- [1,3] DIOXOLO [4,5-F] INDOL-7-YL) PYRROLE-2,5-DIONE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3697794T3 true FI3697794T3 (fi) | 2026-02-10 |
Family
ID=64110166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18797367.2T FI3697794T3 (fi) | 2017-10-16 | 2018-10-16 | 3-(5-fluoribentsofuran-3-yyli)-4-(5-metyyli-5h-[1,3]dioksolo[4,5-f]indol-7-yyli)pyrroli-2,5-dionin kiinteitä muotoja |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11407759B2 (enExample) |
| EP (1) | EP3697794B1 (enExample) |
| JP (2) | JP7776258B2 (enExample) |
| KR (1) | KR102891811B1 (enExample) |
| CN (1) | CN111315748B (enExample) |
| AU (1) | AU2018352384B2 (enExample) |
| CA (1) | CA3074037A1 (enExample) |
| DK (1) | DK3697794T3 (enExample) |
| ES (1) | ES3064009T3 (enExample) |
| FI (1) | FI3697794T3 (enExample) |
| IL (1) | IL273920B2 (enExample) |
| MX (1) | MX2020003431A (enExample) |
| PL (1) | PL3697794T3 (enExample) |
| PT (1) | PT3697794T (enExample) |
| WO (1) | WO2019079299A1 (enExample) |
| ZA (1) | ZA202002740B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3697794T (pt) * | 2017-10-16 | 2026-03-04 | Actuate Therapeutics Inc | Formas sólidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]dioxolo[4,5-f]indol-7-il)pirrol-2,5-diona |
| EP3793545A4 (en) * | 2018-05-17 | 2022-04-06 | Actuate Therapeutics Inc. | TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS WITH BETA INHIBITORS IN THE FORM OF GLYCOGEN SYNTHASE KINASE 3 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2446269T3 (es) | 2006-12-19 | 2014-03-06 | The Board Of Trustees Of The University Of Illinois | 3-Benzofuranil-4-indolil-maleimidas como potentes inhibidores de GSK-3 para trastornos neurodegenerativos |
| CN111247153B (zh) | 2017-08-11 | 2024-04-02 | 开动疗法公司 | 3-(5-氟苯并呋喃-3-基)-4-(5-甲基-5H-[1，3]间二氧杂环戊烯并[4，5-f]吲哚-7-基)吡咯-2，5-二酮的固体形式 |
| PT3697794T (pt) * | 2017-10-16 | 2026-03-04 | Actuate Therapeutics Inc | Formas sólidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]dioxolo[4,5-f]indol-7-il)pirrol-2,5-diona |
-
2018
- 2018-10-16 PT PT187973672T patent/PT3697794T/pt unknown
- 2018-10-16 WO PCT/US2018/056083 patent/WO2019079299A1/en not_active Ceased
- 2018-10-16 ES ES18797367T patent/ES3064009T3/es active Active
- 2018-10-16 AU AU2018352384A patent/AU2018352384B2/en active Active
- 2018-10-16 MX MX2020003431A patent/MX2020003431A/es unknown
- 2018-10-16 CA CA3074037A patent/CA3074037A1/en active Pending
- 2018-10-16 IL IL273920A patent/IL273920B2/en unknown
- 2018-10-16 US US16/755,903 patent/US11407759B2/en active Active
- 2018-10-16 JP JP2020521319A patent/JP7776258B2/ja active Active
- 2018-10-16 FI FIEP18797367.2T patent/FI3697794T3/fi active
- 2018-10-16 KR KR1020207013947A patent/KR102891811B1/ko active Active
- 2018-10-16 EP EP18797367.2A patent/EP3697794B1/en active Active
- 2018-10-16 PL PL18797367.2T patent/PL3697794T3/pl unknown
- 2018-10-16 DK DK18797367.2T patent/DK3697794T3/da active
- 2018-10-16 CN CN201880066706.4A patent/CN111315748B/zh active Active
-
2020
- 2020-05-13 ZA ZA2020/02740A patent/ZA202002740B/en unknown
-
2022
- 2022-07-01 US US17/855,847 patent/US12116374B2/en active Active
-
2023
- 2023-09-19 JP JP2023151499A patent/JP2024001040A/ja active Pending
-
2024
- 2024-09-10 US US18/830,117 patent/US20250115615A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES3064009T3 (en) | 2026-04-22 |
| BR112020007538A2 (pt) | 2020-09-24 |
| JP2020536944A (ja) | 2020-12-17 |
| KR102891811B1 (ko) | 2025-11-28 |
| PT3697794T (pt) | 2026-03-04 |
| IL273920A (en) | 2020-05-31 |
| IL273920B2 (en) | 2025-07-01 |
| AU2018352384A1 (en) | 2020-05-21 |
| WO2019079299A1 (en) | 2019-04-25 |
| DK3697794T3 (da) | 2026-02-02 |
| US20200239489A1 (en) | 2020-07-30 |
| JP2024001040A (ja) | 2024-01-09 |
| CN111315748B (zh) | 2023-06-27 |
| AU2018352384B2 (en) | 2023-12-21 |
| MX2020003431A (es) | 2020-07-29 |
| EP3697794A1 (en) | 2020-08-26 |
| US20250115615A1 (en) | 2025-04-10 |
| EP3697794B1 (en) | 2025-12-24 |
| KR20200100615A (ko) | 2020-08-26 |
| CN111315748A (zh) | 2020-06-19 |
| IL273920B1 (en) | 2025-03-01 |
| CA3074037A1 (en) | 2019-04-25 |
| PL3697794T3 (pl) | 2026-04-07 |
| JP7776258B2 (ja) | 2025-11-26 |
| US20220348591A1 (en) | 2022-11-03 |
| US12116374B2 (en) | 2024-10-15 |
| ZA202002740B (en) | 2025-12-17 |
| US11407759B2 (en) | 2022-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023307645A1 (en) | Fused ring kras inhibitors for treating disease | |
| FI2534153T4 (fi) | 8-fluori-2-{4-[(metyyliamino}metyyli]fenyyli}-1,3,4,5-tetrahydro-6h-atsepino[5,4,3-cd]indol-6-onin suoloja ja polymorfeja | |
| RU2019101220A (ru) | Кристаллические формы соединения триазолопиримидина | |
| CN113474349B (zh) | 作为nrf2活化剂的羟基吡啶并氧氮杂环庚三烯 | |
| RU2020121150A (ru) | Твердые формы ингибитора калликреина плазмы и его солей | |
| JP2019524883A5 (enExample) | ||
| Liao et al. | Design and synthesis of novel soluble 2, 5-diketopiperazine derivatives as potential anticancer agents | |
| JP2016528179A5 (enExample) | ||
| JP2021504310A5 (enExample) | ||
| CN104220437B (zh) | α2肾上腺素受体激动剂 | |
| RU2015118581A (ru) | Лиофилизированные препараты мелфалана флуфенамида | |
| FI3697794T3 (fi) | 3-(5-fluoribentsofuran-3-yyli)-4-(5-metyyli-5h-[1,3]dioksolo[4,5-f]indol-7-yyli)pyrroli-2,5-dionin kiinteitä muotoja | |
| RU2017136715A (ru) | Производное имидазоизоиндола, способ его получения и медицинское применение | |
| FI3665176T3 (fi) | 3-(5-fluoribentsofuran-3-yyli)-4-(5-metyyli-5h-[1,3]dioksolo[4,5-f]indol-7-yyli)pyrroli-2,5-dionin kiinteitä muotoja | |
| JP2015522037A5 (enExample) | ||
| FI3317264T3 (fi) | (S)-[3,4-difluori-2-(2-fluori-4-jodifenyyliamino)fenyyli][3-hydroksi-3-(piperidin-2-yyli)atsetidin-1-yyli]metanonin kiteinen fumaraattisuola | |
| RU2019133577A (ru) | ТВЕРДАЯ ФОРМА (S)-[2-хлор-4-фтор-5-(7-морфолин-4-илхиназолин-4-ил)фенил]-(6-метокси-пиридазин-3-ил)метанола | |
| Zhang et al. | Melohemsines AI, melodinus-type alkaloids from Melodinus hemsleyanus | |
| WO2014164648A4 (en) | Solid state forms of a quinazoline derivative and its use as a braf inhibitor | |
| JP2011515421A5 (enExample) | ||
| JP2017535510A5 (enExample) | ||
| JP2024001040A5 (enExample) | ||
| CA3232656A1 (en) | Crystal form of imidazolinone derivative | |
| CA3095922A1 (en) | Solid-state forms of abemaciclib, their use and preparation | |
| AU2021347913A1 (en) | Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same |